[{"id":"f99d43e2-a88e-46e7-9ba6-67aaeb1cdec6","acronym":"RTOG 1216","url":"https://clinicaltrials.gov/study/NCT01810913","created_at":"2021-01-18T08:01:55.190Z","updated_at":"2025-02-25T13:52:01.448Z","phase":"Phase 2/3","brief_title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","source_id_and_acronym":"NCT01810913 - RTOG 1216","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 613","initiation":"Initiation: 03/22/2013","start_date":" 03/22/2013","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-20"},{"id":"6553092f-70e4-434d-af85-c9de431dfb02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03290937","created_at":"2021-01-18T16:15:28.855Z","updated_at":"2025-02-25T14:07:03.272Z","phase":"Phase 1","brief_title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03290937","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"42eaa2bb-da4a-4921-abda-242b6741daf6","acronym":"KL140-Ⅲ-02-CTP","url":"https://clinicaltrials.gov/study/NCT04835142","created_at":"2021-04-08T13:52:28.774Z","updated_at":"2025-02-25T16:16:06.277Z","phase":"Phase 3","brief_title":"Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC","source_id_and_acronym":"NCT04835142 - KL140-Ⅲ-02-CTP","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type • BRAF V600 wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Datalai (cetuximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 688","initiation":"Initiation: 12/31/2020","start_date":" 12/31/2020","primary_txt":" Primary completion: 03/22/2023","primary_completion_date":" 03/22/2023","study_txt":" Completion: 01/26/2024","study_completion_date":" 01/26/2024","last_update_posted":"2024-08-05"},{"id":"9d379a3d-e6e5-4272-912a-3b641b499609","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616183","created_at":"2021-01-19T20:33:33.700Z","updated_at":"2024-07-02T16:35:00.055Z","phase":"Phase 1/2","brief_title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04616183","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • MAP2K1","pipe":"","alterations":" ","tags":["KRAS • BRAF • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"a5424fdf-c39b-40c9-8a83-9dfa8d3d153b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01468896","created_at":"2021-01-18T06:06:56.156Z","updated_at":"2024-07-02T16:35:11.792Z","phase":"Phase 1/2","brief_title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01468896","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 10/26/2011","start_date":" 10/26/2011","primary_txt":" Primary completion: 09/29/2015","primary_completion_date":" 09/29/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-04-02"},{"id":"38bc6aec-e997-4b4f-bc6e-6def457d809b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04017650","created_at":"2021-01-18T19:43:51.552Z","updated_at":"2024-07-02T16:35:20.001Z","phase":"Phase 1/2","brief_title":"Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04017650","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/14/2019","start_date":" 06/14/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-02-09"},{"id":"d32a1468-1f32-43bb-a26b-bca539472397","acronym":"REVERCE II","url":"https://clinicaltrials.gov/study/NCT04117945","created_at":"2021-01-18T20:07:37.386Z","updated_at":"2024-07-02T16:35:20.490Z","phase":"Phase 2","brief_title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04117945 - REVERCE II","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 03/03/2020","start_date":" 03/03/2020","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-02-07"},{"id":"5fe5159d-8c9f-41cf-ba3c-cba707c02cca","acronym":"BOND-3","url":"https://clinicaltrials.gov/study/NCT02292758","created_at":"2021-01-18T10:48:24.367Z","updated_at":"2024-07-02T16:36:17.796Z","phase":"Phase 2","brief_title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02292758 - BOND-3","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • RAS wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • irinotecan • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Datalai (cetuximab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 12/12/2014","start_date":" 12/12/2014","primary_txt":" Primary completion: 03/20/2019","primary_completion_date":" 03/20/2019","study_txt":" Completion: 09/27/2019","study_completion_date":" 09/27/2019","last_update_posted":"2022-01-31"},{"id":"c8ff45fc-0318-40cc-8ebd-bc96f5654bdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04411121","created_at":"2021-01-18T21:16:05.423Z","updated_at":"2024-07-02T16:36:43.820Z","phase":"Phase 2/3","brief_title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-risk Head and Neck Cancer","source_id_and_acronym":"NCT04411121","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 613","initiation":"Initiation: 03/18/2013","start_date":" 03/18/2013","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":"","study_completion_date":"","last_update_posted":"2020-06-25"},{"id":"00adb883-c889-477d-b8e0-365b7242c8b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01254617","created_at":"2021-01-18T05:03:32.491Z","updated_at":"2024-07-02T16:36:48.662Z","phase":"Phase 1","brief_title":"Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","source_id_and_acronym":"NCT01254617","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • lenalidomide • Datalai (cetuximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 02/10/2011","start_date":" 02/10/2011","primary_txt":" Primary completion: 01/29/2014","primary_completion_date":" 01/29/2014","study_txt":" Completion: 01/29/2014","study_completion_date":" 01/29/2014","last_update_posted":"2020-03-13"},{"id":"0bf022e3-2504-4bd9-ab06-f6c2ad181d2c","acronym":"KL140-III-01","url":"https://clinicaltrials.gov/study/NCT03426371","created_at":"2021-01-18T16:54:11.832Z","updated_at":"2025-02-25T16:15:44.799Z","phase":"Phase 3","brief_title":"Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial","source_id_and_acronym":"NCT03426371 - KL140-III-01","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" BRAF • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type • RAS wild-type • BRAF V600 wild-type","tags":["BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type • RAS wild-type • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • leucovorin calcium • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 570","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2018-02-08"}]